TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02029924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro
Description: Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
Study: NCT03361540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT03741959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
Study: NCT02488512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-DOTATOC
Description: Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
Study: NCT02155439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: antimitotic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Study: NCT02143622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LJM716
Description: antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: antibody
Study: NCT01804556

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Myofascial trigger point injections on gastrocnemius muscle
Description: On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 \~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
Study: NCT02047617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the standard physiotherapy group
Description: Mobilization and rehabilitation program is progressively introduced after clinical stabilization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standing table group
Description: The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
Study: NCT03895853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: early metabolic resuscitation
Description: Given Intravenous
Study: NCT02096055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study: NCT03474640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part A
Description: Part A: 80, 240, and 480 mg IV every 14 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part B
Description: Part B: 240 mg IV every 3 weeks
Study: NCT03203265

Intervention type: OTHER
Group type: OTHER
Intervention: Group A: Offline HTC
Description: Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.

Intervention type: OTHER
Group type: OTHER
Intervention: Group B1: Offline HIV testing and post-test counseling
Description: participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.

Intervention type: OTHER
Group type: OTHER
Intervention: Group B2: Online HIV testing and post-test counseling
Description: A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
Study: NCT04175691

Intervention type: GENETIC
Intervention: Sequencing of circRNA/miRNA/lncRNA
Description: Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)

Intervention type: GENETIC
Intervention: Sequencing of circRNA/miRNA/lncRNA
Description: Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
Study: NCT04234516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film
Description: 3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate 30 mg
Description: oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
Study: NCT02810496

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood collection for mutation characterization
Study: NCT03877848

Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention (PCI)
Description: Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
Study: NCT04509596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C
Description: Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD.~Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle.~Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days
Study: NCT00568516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3550
Description: subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3550
Description: subcutaneous administration
Study: NCT03681769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS to the left dlPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS to the left dlPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study: NCT00070707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo nasal spray, administered QD as 2 sprays in each nostril.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
Study: NCT01114386

Intervention type: PROCEDURE
Intervention: Lung function testing, echocardiography, blood sampling
Description: All patients will undergo to:~* physical examination~* 6' Minute Walk test~* pulmonary function testing (spirometry + volumes and reversibility testing)~* carbon monoxide diffusing capacity (DLCO) with single-breathe technique~* ECG~* echocardiography
Study: NCT02780817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error enhancement
Description: Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
Study: NCT03372772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
Study: NCT03590691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vietnam National Hypertension Program
Description: A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vietnam National Hypertension Program
Description: A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expanded community health worker services
Description: A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling intervention
Description: The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home blood pressure self-monitoring
Description: Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
Study: NCT04440631

Intervention type: OTHER
Intervention: no intervention, observational only
Description: no intervention, observational only

Intervention type: OTHER
Intervention: no intervention, observational only
Description: no intervention, observational only

Intervention type: OTHER
Intervention: no intervention, observational only
Description: no intervention, observational only
Study: NCT01257737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
Study: NCT02096055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study: NCT03433456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visitation + HABITS program
Description: The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard home visitation program
Description: Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard home visitation program
Description: Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
Study: NCT04749121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVC Irradiation
Description: We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UVC Irradiation
Description: Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fit test
Description: All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tensile strength
Description: We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
Study: NCT03943199

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual Analogue Scale for pain
Description: Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual Analogue Scale for pain
Description: Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual Analogue Scale for pain
Description: Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Visual Analogue Scale for pain
Description: Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
Study: NCT02265640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS boli

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS boli

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS tablet C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS tablet C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard breakfast
Study: NCT01455675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgY
Description: Avian polyclonal anti-pseudomonas antibodies (IgY)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 70 ml gargling solution, once daily
Study: NCT02675452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Non-investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Non-investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Non-investigational product
Study: NCT00886093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
Study: NCT01637207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palpation
Description: Group A: Palpation Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Group B: Ultrasound Group
Study: NCT01591902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Description: Daily 2 mg subcutaneous injections of tesamorelin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: 3.0 mL vials
Study: NCT00124579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 100 mg/d PO days 1-21 every 21 days